Barry C. Mirtsching, MD at CORT is the lead investigator for the International Oncology Network (ION) trial of Abraxane and sorafenib (Nexavar) for first-line treatment of metastatic breast cancer. Nexavar is an oral drug with anti-angiogenic and anti-proliferative activity in cancer. It is FDA-approved in the treatment of metastatic renal (kidney) cancer. Nexavar has single-agent activity demonstrated in a phase II study in metastatic breast cancer. The combination of anti-angiogenic drugs and chemotherapy has shown promise in breast cancer treatment. The ION phase II study will test the efficacy of the Abraxane and Nexavar combination therapy for first-line treatment of metastatic breast cancer. The risks of treatment include fatigue, rash, allergic reaction, nausea, vomiting, diarrhea, sensory neuropathy, increased blood pressure, slow wound healing, proteinuria, thrombosis, bleeding, and low blood counts.
For more information on these studies, visit www.CORTPA.com, or speak with a Study Coordinator at 972-566-5588.
Tags: Abraxane, Breast Cancer, International Oncology Network, metastatic breast cancer, nab-paclitaxel, Nexavar, sorafenib
